Clinical trials: Imipenem
Complicated Urinary Tract Infection Including Acute Pyelonephritis
Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)
This is A Multicenter, Randomized, Double-Blind, Double-Dummy, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin/Funobactam in Comparison with Meropenem in Hospitalized Adults with…
- Trial name
- NCT05204368
- Testing
- Combination of Imipenem/Cilastatin and XNW4107, Meropenem
- Where
- United States
- Volunteers
- 780 people
- Sponsor
- Evopoint Biosciences Inc.
Pneumonia
Evaluation of Innovative Tools in Development of Antibiotics
The investigators will determine the difference of pharmacokinetics of ciprofloxacin and imipenem between healthy volunteers and intensive care patients suffering from pneumonia in plasma and at the target site - lung - using…
- Trial name
- NCT03177720
- Testing
- Ciprofloxacin, Imipenem
- Where
- Austria
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Methicillin-resistant Staphylococcus Aureus, Pneumonia, Ventilator-Associated
Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia
As previous studies showed that the synergy between linezolid and carbapenem in vitro and in vivo (animal studies), our study is aim to investigate the activity of linezolid, alone and in combination with carbapenem against…
- Trial name
- NCT01356472
- Testing
- Imipenem/cilastatin
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Ceftolozane/Tazobactam, Imipenem/Relebactam
In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients
The purpose of the ACTHEON Study is to evaluate the in vitro activity of ceftolozane-tazobactam, imipenem-relebactam and comparator agents (amoxicillin- clavulanate, piperacillin-tazobactam, ceftazidime, cefotaxime, cefepime…
- Conditions
- Ceftolozane/Tazobactam, Imipenem/Relebactam, Hematology and Oncology
- Trial name
- ACTHEON (NCT04196608)
- Testing
- Ceftolozane/tazobactam, imipenem- relebactam
- Where
- Spain
- Volunteers
- 1,005 people
- Sponsor
- Emilio Bouza
Beta-lactam Antibiotics, Therapeutic Drug Monitoring
The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring
Little is known of beta-lactam antibiotics' true therapeutic plasma concentration range. The aims of this study are to define evidence-based, safe and effective upper and lower limits of the plasma concentrations of imipenem…
- Conditions
- Beta-lactam Antibiotics, Therapeutic Drug Monitoring, Toxicity, Efficacy
- Trial name
- OPTIMAL TDM (NCT03790631)
- Testing
- The study is observational.
- Where
- Switzerland
- Volunteers
- 771 people
- Sponsor
- University of Geneva, Switzerland
Pneumonia, Bacterial
Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia
This study will compare the safety and efficacy of a tigecycline regimen versus an imipenem/cilastatin regimen for the treatment of subjects who are hospitalized with hospital-acquired pneumonia (HAP).
- Trial name
- NCT00707239
- Testing
- tigecycline, imipenem/cilastatin
- Where
- 40 sites in United States, Argentina and 12 more
- Volunteers
- 108 people
- Sponsor
- Pfizer
Urinary Tract Infections
Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli
Background Information: Infections caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli are becoming increasingly common owing to incorrect use of antibiotics and cross-transmission in healthcare…
- Trial name
- COLIFOX (NCT02474706)
- Testing
- Cefoxitin, imipenem
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Central Hospital, Nancy, France
Antibacterial Prophylaxis, Hematological Malignancies
Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematologic malignancies.
- Conditions
- Antibacterial Prophylaxis, Hematological Malignancies, Allogenetic Hematopoietic Stem Cell Transplantation, Imipenem
- Trial name
- NCT03733340
- Testing
- Imipenem
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Sepsis
Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance
Critically ill patients with sepsis undergo several physiological alterations that can alter the distribution, metabolism, and elimination of drugs.
- Trial name
- NCT04147221
- Testing
- Imipenem-relebactam
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Hartford Hospital
Febrile, Neutropenia
Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia
Neutropenia is very common in patients received hematopoietic stem cell transplantation, with median duration of about 14 days. In 2010 update, IDSA recommended Piperacillin/tazobactam as first-line mono-therapy for febrile…
- Conditions
- Febrile, Neutropenia, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT01714570
- Testing
- Piperacillin-tazobactam combination product, Imipenem
- Where
- China
- Volunteers
- 123 people
- Sponsor
- Chinese PLA General Hospital
Ventilator Associated Pneumonia
Impact of Imipenem With Amikacin Pharmacokinetic and Pharmacodynamic
The study is a prospective open trial conducted in 4 centers, and designed to determine if pharmacokinetic (PK) and pharmacodynamic (PD) parameters of imipenem, associated with amikacin as empirical therapy, impact…
- Trial name
- IMPACT (NCT00950222)
- Testing
- Imipenem/Amikacin
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Urinary Tract Infection, Acute Pyelonephritis
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
The primary purpose of this study is to assess the efficacy of oral TBP-PI-HBr as compared with intravenous (IV) imipenem-cilastatin with respect to the overall response (combined clinical cure plus microbiological eradication)…
- Trial name
- PIVOT-PO (NCT06059846)
- Testing
- TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion
- Where
- 85 sites in United States, Argentina and 17 more
- Volunteers
- 1,690 people
- Sponsor
- Spero Therapeutics
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
This phase II trial studies the effect of imipenem-relebactam in treating patients with cancer who have a fever due to low white blood cell counts (febrile neutropenia).
- Trial name
- NCT04983901
- Testing
- Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Transplantation
Pharmacokinetics of Imipenem During Ex Vivo Lung Perfusion (EVLP)
Ex vivo lung perfusion (EVLP) is an established strategy to evaluate and optimize high-risk donor lungs that would otherwise be rejected for transplantation mainly due to the presence of edema or infection.
- Trial name
- NCT02670239
- Testing
- normothermic ex vivo lung perfusion
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy
Spontaneous Bacterial Peritonitis
A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.
Study population: A total of 90 consecutive patients of decompensated cirrhosis of any etiology, presenting to the Institute of Liver and Biliary Sciences with SBP with septic shock will be included.
- Trial name
- NCT04208763
- Testing
- Imipenem, Tigecycline, GMCSF
- Where
- India
- Volunteers
- 90 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Critical Illness, Bacterial Infections
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
Meropenem and imipenem are broad-spectrum carbapenem antibiotic and are frequently prescribed in critically ill patients with severe infections.
- Trial name
- NCT03858387
- Testing
- Meropenem, Imipenem
- Where
- Thailand
- Volunteers
- 102 people
- Sponsor
- Prince of Songkla University
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
This study aims to compare treatment with Imipenem/Cilastatin-XNW4107 (IMI-XNW4107) with imipenem/cilastatin/relebactam (IMI/REL) in participants with hospital-acquired or ventilator-associated bacterial pneumonia (HABP or VAPB…
- Trial name
- REITAB-2 (NCT05204563)
- Testing
- Combination of Imipenem/Cilastatin and XNW4107, Imipenem/Cilastatin/Relebactam
- Where
- 35 sites in United States, France and 2 more
- Volunteers
- 450 people
- Sponsor
- Evopoint Biosciences Inc.
Bacterial Infections
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (MK-7655A) versus colistimethate sodium+imipenem+cilastatin in the treatment of imipenem-resistant bacterial infections.
- Trial name
- RESTORE-IMI 1 (NCT02452047)
- Testing
- Imipenem+Cilastatin/Relebactam, Colistimethate sodium (CMS), Imipenem+Cilastatin
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Carbapenem-Resistant Enterobacteriaceae Infection, KPC
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
This is an observation study comparing prospective use of Imipenem/Cilastatin/Relebactam (IMI/REL) to retrospective data using Meropenem/Vabobactam (MVB)and Ceftazidime/Avibactam CZA) in treatment of Klebsiella Producing…
- Conditions
- Carbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections, Antibiotic Resistant Infection
- Trial name
- NCT04785924
- Testing
- Imipenem+Relebactam
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Gram Negative Organism
Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC
The isolate samples will be collected over a period of one year once IRB approval has been obtained. These isolates were collected as part of the patient's clinical care and once all clinical testing is complete, all isolates…
- Trial name
- NCT00443885
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- University of Pittsburgh